Physician profile
David B Shanker
NPI 1619905734
$4,984.73
in general payments reported to CMS, 2019-2025
31 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $81.67 · 2021: $286 · 2022: $739 · 2023: $994 · 2024: $1,490 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.69 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.16 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $653.08 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $579.97 | 2019-2025 | |
| Dermavant Sciences, INC. | $430.77 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $317.38 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $294.68 | 2020-2025 | |
| Amgen INC. | $247.77 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $228.90 | 2022-2024 | Opzelura |
| Pfizer INC. | $203.67 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $196.85 | 2019-2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $163.17 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $127.86 | 2022-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $102.80 | 2021-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Ucb, INC. | $82.54 | 2019-2025 | Bimzelx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $80.20 | 2023-2025 | Tremfya |
| Organon LLC | $70.62 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $69.55 | 2024-2025 | |
| Biofrontera INC. | $69.51 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $48.42 | 2025 | Zoryve |
| Organogenesis INC. | $44.18 | 2023-2024 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.47 | 2023-2024 | Spevigo |
| Celgene Corporation | $40.19 | 2019 | |
| Blueprint Medicines Corporation | $22.02 | 2024 | Ayvakit |
| Dermira, INC. | $18.33 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.93 | 2019 | |
| Epi Health, LLC | $16.32 | 2022 | |
| Journey Medical Corporation | $14.43 | 2025 | |
| Leo Pharma INC. | $13.90 | 2023 | Adbry |
| Genentech USA, INC. | $13.03 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shanker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.